Barclays PLC Buys 301,389 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)

Barclays PLC lifted its position in Fate Therapeutics, Inc. (NASDAQ:FATE) by 245.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 424,277 shares of the biopharmaceutical company’s stock after acquiring an additional 301,389 shares during the quarter. Barclays PLC owned approximately 0.37% of Fate Therapeutics worth $1,485,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in FATE. Massachusetts Financial Services Co. MA boosted its holdings in Fate Therapeutics by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 167,055 shares of the biopharmaceutical company’s stock worth $548,000 after purchasing an additional 5,605 shares during the last quarter. Doheny Asset Management CA purchased a new position in shares of Fate Therapeutics in the 2nd quarter worth approximately $263,000. Ausdal Financial Partners Inc. purchased a new position in shares of Fate Therapeutics in the 2nd quarter worth approximately $33,000. Exchange Traded Concepts LLC grew its holdings in shares of Fate Therapeutics by 40.7% in the third quarter. Exchange Traded Concepts LLC now owns 42,289 shares of the biopharmaceutical company’s stock valued at $148,000 after acquiring an additional 12,230 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Fate Therapeutics by 11.0% during the second quarter. Rhumbline Advisers now owns 160,001 shares of the biopharmaceutical company’s stock valued at $525,000 after acquiring an additional 15,825 shares during the last quarter. Hedge funds and other institutional investors own 97.54% of the company’s stock.

Fate Therapeutics Stock Performance

Shares of Fate Therapeutics stock opened at $1.61 on Friday. The stock has a market capitalization of $183.37 million, a P/E ratio of -0.98 and a beta of 1.95. Fate Therapeutics, Inc. has a 52-week low of $1.56 and a 52-week high of $8.83. The stock’s 50-day simple moving average is $2.38 and its 200 day simple moving average is $3.26.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.02. The company had revenue of $3.07 million for the quarter, compared to analyst estimates of $0.88 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. Equities research analysts forecast that Fate Therapeutics, Inc. will post -1.72 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Redmile Group, Llc bought 397,964 shares of Fate Therapeutics stock in a transaction on Friday, December 20th. The stock was acquired at an average price of $1.68 per share, with a total value of $668,579.52. Following the acquisition, the director now directly owns 12,884,277 shares of the company’s stock, valued at $21,645,585.36. This represents a 3.19 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 5.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on FATE. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a research report on Tuesday, November 19th. Wedbush reissued a “neutral” rating and issued a $5.00 price target on shares of Fate Therapeutics in a report on Tuesday, November 12th. Finally, Bank of America upgraded shares of Fate Therapeutics from an “underperform” rating to a “neutral” rating in a report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $6.75.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.